Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

The global phosphorus-enriched organic manure market size is expected to grow significantly, with its value increasing from USD 3,382.9 million in 2024 to USD 6,347.6 million by 2034. This growth ...

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

Trump Officials Fire Jan. 6 Prosecutors and Plan Possible F.B.I. Purge The move to scrutinize thousands of F.B.I. agents was a powerful indication that President Trump has few qualms deploying law ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

Images reveal a day of celebration for Donald Trump as tech tycoons and cheering crowds alike hail another four years of Maga-mania ...